非布司他治痛风效果

(Febuxostat) is a selective inhibitor of non-purine xanthine oxidase/xanthine dehydrogenase. In the 2012 American College of Rheumatology Gout Guidelines, febuxostat is recommended as a Class A recommendation for drug treatment of patients with hyperuricemia and gout, which is the first-line option. In June 2013, China's State Food and Drug Administration approved febuxostat for marketing in China. How effective is febuxostat in treating gout?

Febuxostat is indicated for the long-term treatment of hyperuricemia in patients with gout. Not recommended for use in asymptomatic hyperuricemia. There are no studies on the use of this product in patients with secondary hyperuricemia (including organ transplant recipients), so it is not recommended to use this product in patients with massively elevated urate levels (such as malignant diseases, Lesch-Nyhan syndrome).

The clinical data of 40 gout patients admitted to the Endocrinology Department of the Affiliated Hospital of Zunyi Medical College from January 2016 to December 2017. All case data are continuous and complete. According to the medication status of the patients, they were divided into febuxostat group and allopurinol group, with 20 cases in each group. Patients in the febuxostat group took febuxostat tablets orally, and patients in the allopurinol group took orally allopurinol. The serum uric acid levels, gout symptom improvement, post-treatment clinical effects and adverse reactions of the two groups of patients before and after treatment were observed.

Results When comparing the serum uric acid levels of the two groups of patients before treatment, there was no statistically significant difference (P>0.05); after treatment, the serum uric acid level of the patients in the febuxostat group [(372.55±90.80) μmol/L] was lower than that of the allopurinol group [(413.25±141.31) μmol/L], and the difference was statistically significant (P<0.05). The serum uric acid compliance rate (55.0%) and symptom improvement rate (95.0%) of patients in the febuxostat group were higher than those in the allopurinol group (35.0%, 85.0%), and the differences were statistically significant (P<0.05). The incidence of adverse reactions in the febuxostat group (20.0%) was lower than that in the allopurinol group (30.0%), and the difference was statistically significant (P<0.05). The conclusion shows that the efficacy and safety of febuxostat in the treatment of gout are more advantageous than allopurinol, and it is worthy of clinical promotion and application.

Currently, there are three main clinical drugs for the treatment of gout (uric acid-lowering): allopurinol, febuxostat, and benzbromarone. The effect of treating gout is remarkable. Therefore, when it comes to the choice of acid-lowering drugs for gout, many patients tend to choose febuxostat. Patients who want more drug information about febuxostat can contact Medical Companion Travel.